Accu-Break Pharmaceuticals, Inc.

Setting The Standard  For Dose Flexibility

Contact Us

Creating Tablets That Allow Dose Flexibility

Setting the Standard for Dose Flexibility

The Simplicity is Startling

The Applicability is Astonishing

ACCU-BREAK™ Pharmaceuticals, Inc. ("ABP" or the “Company”) is a privately-held pharmaceutical company. ABP has invented and is developing the patent-pending ACCU-BREAK™ family of technologies (the "Technologies"). ACCU-BREAK™ tablets are designed to improve and enhance the functionality of pharmaceutical tablets.

While being manufactured to be easily swallowed as whole tablets, the Company expects ACCU-BREAK™ tablets to be “Simply Better™” because in addition, they are “Made to be Broken™.” The ACCU-BREAK™ innovations are designed to allow pharmaceutical tablets to be able to be easily broken into equal half, third, or quarter doses.

The Company believes that many existing and pipeline pharmaceutical products may be able to gain enhanced competitive positioning and improved patent protection by formulating products according to the ACCU-BREAK™ principles.

The core insight of the Technologies is creation of an inactive segment of a pharmaceutical tablet that serves as the breaking region if a smaller dose, such as a half dose, is desired. Thus, inaccurate breaking of the tablet does not affect dosing, because the break region is pharmacologically inactive.

The Company has also filed patents on several branded product ideas, and has developed formulations for certain branded product candidates.

ABP is led by an experienced and successful Management team and Directors, and is advised by a well-respected Scientific Advisory Board.

Maximize your Product's Value with Accu-Break™ Technologies

Drug reformulations, line extensions and combination therapies have become increasingly popular product life cycle management strategies.

  • Ease of dividing into precise smaller doses ideal for pediatric and geriatric patients
  • Eliminate tablet splitting concerns such as unpredictable doses and loss of mass
  • Controlled-release formulations may bolster compliance, possibly improving outcomes and overcoming therapeutic inertia
  • Accu-Break CR tablets offer additional benefits over conventional CR tablets
  • Accu-Break™ technologies provide multiple opportunities for life cycle management
  • Leverage Accu-Break's patent portfolio for extending or adding product exclusivity
  • Increase chances of early market adoption with beneficial Accu-Break feature reformulation
  • Reposition your drugs with new or improved clinically relevant benefits
  • Ease of dividing and precision dose adjustments preferred among physicians and patients
  • Significant anti-counterfeiting properties

Leadership Team

Robert I. Goldfarb President, General Counsel & Director

Robert I. Goldfarb
President, General Counsel & Director

Mr. Goldfarb has been a Director of Accu-Break since 2018. He has over 39 years of legal experience, with much of that focused on the pharmaceutical industry. Before joining Accu‑Break, he was Senior Vice President and General Counsel of Andrx Corporation. Prior to that, he was a partner with the law firm of Hughes, Hubbard & Reed.

He is a board member and legal consultant for several private pharmaceutical companies.

Mr. Goldfarb obtained his Bachelor’s Degree from the University of Connecticut and his J.D. from the University of Florida. He is a member of the Florida Bar.

Sidney J. Feltenstein Director

Sidney J. Feltenstein
Director

Mr. Feltenstein has been a Director of Accu-Break since 2016. Mr. Feltenstein has had a wide-ranging career as a traditional corporate executive, a successful entrepreneur and a supporter of non-profit entities.

Mr. Feltenstein began his career at the Procter and Gamble Company where he has held several brand management positions. He has also spent time with what is now Bozell as an Account Executive and Account Supervisor. He then became Director of Marketing for the Speidel Division of Textron and then Vice President of Marketing for Candy Corporation of America.

Mr. Feltenstein has a great track record for rejuvenating brands. In 1995 he led an investment group that bought A&W Restaurants from real estate magnate Alfred Taubman. Under Mr. Feltenstein’s leadership, the chain grew from 450 to almost 1,000 units in just five years. In 1999, he and his investment group purchased Long John Silver’s and formed Yorkshire Global Restaurants, the holding company for A&W Restaurants and Long John Silver’s. The company’s sales grew five times and its operating profits grew by 40 times. In 2002, he sold this company to YUM Brands.

After leaving YUM Brands, Mr. Feltenstein founded a new company, Sagittarius Brands and acquired Captain D’s Restaurants and Del Taco Restaurants. After combining the two companies and installing a management team, he left to pursue other projects.

Mr. Feltenstein is a graduate of Boston University, a former Trustee of that institution and former Chairman of its Audit Committee. He is also a member of the Board of Advisors for Boston University’s School of Hospitality Administration and was Chairman of its Board from 1988 to 1991. He is past Chairman of the International Franchise Association (IFA) and former Chairman of the IFA Educational Foundation. He is the recipient of IFA’s Entrepreneur of the Year Award and a member of its Hall of Fame.

He is a member of the Board of Directors of One Family Health and a number of for-profit companies.

David Beach Technical Consultant

David Beach
Technical Consultant

Dr. David Beach has 30+ years of experience working in the pharmaceutical industry and Health Sciences area He is the former President and CEO of TorPharm, the US. division of Apotex Inc. He grew this from a "greenfield start-up" to over $400 million in revenue and 1,000+ employees during his decade long tenure as President.

Dr. Beach was also a senior scientist with DuPont pharmaceuticals and a key participant in the design and qualification of a new pharmaceutical research facility in Winnington, Delaware. He managed a new product development group and was also possible for the preparation of Clinical Supplies for Phase I through Phase Ill clinical studies of DuPont's new chemical entity program during this time. During his tenure at DuPont he was a co-inventor on two U.S. patents in ffe area of polymer mediated sustained release technology. Prior to joining the Apotex Group, Dr. Beach held a number of progressive positions with Superpharm Corporation, a Division of Goldine Laboratories, and Schering-Plough in both veterinary and human health divisions. Dr. Beach regularly sought by investors, academics and media for advice and insights on global trends & and issues in pharmaceutical operations and policy.

Dr. Beach holds a BS in Pharmacy from Union University, Albany College of Pharmacy and a PhD in pharmaceutics from the University of Maryland at Baltimore, specializing in physical pharmacy and dosage form development.

Nigel N. Norton Director

Nigel N. Norton
Director

Mr. Norton has been a Director of Accu-Break since 2003. He was a founder of H N Norton Ltd which was established in 1960 as a branded proprietary pharmaceutical company. Under his direction, the company evolved into the emerging generic pharmaceutical business and, as NORTON HEALTHCARE Ltd. became the dominant generic pharmaceutical company in the UK, and an industry leader in Europe. In 1990 the company merged with IVAX Corporation. Mr. Norton was a director of IVAX from 1990 to 1993.

Mel Harris Director

Mel Harris
Director

Mel Harris founded Preferred Employers in 1996, and serves as its Chairman and Chief Executive Officer. Prior to that, Mr. Harris served as Vice Chairman of Jardine Insurance Brokers New York, Inc. from February 1992 until January 994. From 1988 until February 1992, Mr. Harris served as Vice Chairman of Alexander & Alexander of New York, Inc. (a wholly-owned subsidiary of A&A Services, Inc), a global insurance brokerage organization.

He served as President of International Insurance Group, Inc. since 1984. He served on the Board of Directors of the National Parkinson Foundation and currently serves on the Board of the Hebrew Home for the Aged in Riverdale New York, and the Yeshiva University Sy Syms School of Business. Mr. Harris is an active member of the Washington Business Forum. He is a founder of the United States Holocaust Memorial Museum, Washington, D.C. and a 1994 recipient of the Ellis Island Medal of Honor Award. Mr. Harris is also a director and shareholder of Strategica Capital Corp, a merchant banking firm. Mr. Harris attended the University of Miami. He is a successful entrepreneur, real estate inventor and developer as well as a venture capitalist.

Lloyd A Moriber, MD Director

Lloyd A Moriber, MD
Director

Dr. Lloyd A Moriber was a founder and Director of Palmetto General Hospital located in Hialeah, Florida. He also was a past Trustee and Honorary Trustee of Mount Sinai Hospital located in Miami Beach, Florida. Dr. Moriber practiced as an orthopedic surgeon from April 1967 through August 2005.

He is a Diplomat of the American Board of Orthopedic Surgery, a Fellow of the American Academy of Orthopedic Surgeons, a Fellow of the American College of Surgeons, a Fellow of the International College of Surgeons and a
Member of the Royal Society of Health. He is also a founding patron of the Adrienne Arsht Center for the Performing Arts in Miami, Florida. He graduated from Duke University School of Medicine in 1961 and was an assistant resident at Yale University Medical School and resident at Hospital for Special Surgery at Cornell University.